Beta-adrenergic receptor activity in ponies with recurrent obstructive pulmonary disease.
Pulmonary function measurements were made in control ponies and in ponies with recurrent obstructive pulmonary disease (principals) during clinical remission and during an attack of acute airway obstruction. The ponies were given beta-adrenergic antagonists and agonists to determine the role of beta receptors in recurrent obstructive pulmonary disease, and to determine the subtypes of beta receptors mediating bronchodilation in ponies. Aerosol administration of the beta antagonists, propranolol (beta 1 and beta 2), atenolol (beta 1), and butoxamine (beta 2) decreased dynamic compliance (Cdyn) and increased pulmonary resistance (RL) in the principal ponies during airway obstruction, but were without effect when the ponies were in clinical remission. Intravenous administration of atropine reversed the effect of atenolol on Cdyn and RL, but was without effect on the decrease in Cdyn and increase in RL observed after butoxamine administration. The beta antagonists did not affect airway function in the control ponies. The effect of beta blockade on Cdyn and RL suggests beta-adrenergic activation in the central and peripheral airways of principal ponies, mediated through both beta 2- and beta 1-adrenergic receptors. The aerosol beta agonists, isoproterenol (beta 1 and beta 2), and clenbuterol (beta 2) attenuated histamine-induced airway obstruction to a similar extent in control ponies that were given histamine IV. In addition, the beta 1 antagonist, atenolol, did not attenuate the bronchodilation observed with isoproterenol. We concluded that, although beta 1- and beta 2-adrenergic receptors exist in pony airways and are activated during acute airway obstruction, bronchodilation in response to beta agonists in ponies seems to be mediated primarily by beta 2-adrenergic receptors.
Scott
J S
JS
Department of Large Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing 48824-1314.
Berney
C E
CE
Derksen
F J
FJ
Robinson
N E
NE
D000336:Aerosols; D000818:Animals; D001262:Atenolol / Q000008:administration & dosage / Q000494:pharmacology; D002078:Butoxamine / Q000008:administration & dosage / Q000494:pharmacology; D006632:Histamine / Q000008:administration & dosage / Q000494:pharmacology; D006734:Horse Diseases / Q000503:physiopathology*; D006736:Horses; D007545:Isoproterenol / Q000008:administration & dosage / Q000494:pharmacology; D008173:Lung Diseases, Obstructive / Q000503:physiopathology / Q000662:veterinary*; D011433:Propranolol / Q000008:administration & dosage / Q000494:pharmacology; D011943:Receptors, Adrenergic, beta / Q000032:analysis / Q000187:drug effects / Q000502:physiology*; D012008:Recurrence; D012129:Respiratory Function Tests / Q000662:veterinary
D000336:Aerosols; D011943:Receptors, Adrenergic, beta; D002078:Butoxamine; D001262:Atenolol; D006632:Histamine; D011433:Propranolol; D007545:Isoproterenol